Abstract
Interindividual differences for outcomes of lipid-lowering therapy are well known. Alterations in cellular pathways may contribute to the phenomenon. To address this question, we employed an automated multiplexed analysis pipeline to systematically characterize alterations in cellular lipid trafficking in leukocytes from 400 subjects of the FINRISK 2012 Study. Of individuals receiving high-intensity statin therapy those with lower cellular lipid trafficking scores displayed higher circulating concentrations of several pro-atherogenic lipoproteins and had higher odds for myocardial infarction and stroke when compared to the rest of the subjects with equivalent treatment. Most subjects with a poor lipid trafficking score did not reach low density lipoprotein cholesterol (LDL-C) target levels on statin monotherapy. Lipid trafficking scores showed synergy with a polygenic risk score for LDL-C, improving the association with pro-atherogenic lipoprotein profile when combined. Our results suggest that quantification of cellular lipid trafficking can aid in treatment selection and risk assessment in dyslipidemia.
Competing Interest Statement
A patent application covering the use of the here-suggested patient stratification methods has been filed (application: WO2022123120A1), in which University of Helsinki is the applicant and S.G.P. is an inventor.
Funding Statement
Grants from the Academy of Finland 328861 and 325040, Business Finland (Research to Business) 1821/31/2021, Magnus Ehrnrooth and the Foundation for Cardiovascular Research to S.G.P. Grants from Academy of Finland Center of Excellence in Complex Disease Genetics 312062, Academy of Finland 285380, the Finnish Foundation for Cardiovascular Research and the Sigrid Jusélius Foundation to S.R. Funding from the Doctoral Programme in Population Health, University of Helsinki to M.T.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Peripheral blood mononuclear cell (PBMC) samples were cryopreserved in 2012 as a part of Finnish population survey, FINRISK 2012, with written consent and ethical approval of the Hospital District of Helsinki and Uusimaa (permit 162/13/03/00/2011). The FINRISK 2012 sample collection was then transferred to THL Biobank in 2015. Frozen PBMC samples, pseudonymised donor-linked lipid values and survey data were obtained then from THL Biobank (www.thl.fi/biobank) and used under Biobank agreement (THLBB2020_7). The rigister-based pseudynymised data was obtained under permit (THL/4640/14.02.00/2020) from the Finnish Social and Health Data Permit Authority Findata.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract was shortened. Discussion was rewritten to add clarity.
Data availability statement
The data used in this research includes sensitive personal health information and is therefore under restricted access. Biological samples and linked laboratory lipid values, questionnaire answers and biometrics as well as genetic data underlying this article were provided by THL Biobank (www.thl.fi/biobank) and used under Biobank agreement THLBB2020_7. Access to the data can be obtained from the THL Biobank through the standard application procedure. The register-based data including diagnoses, causes of death and medication purchase history used in this study can be obtained from the Finnish Social and Health Data Permit Authority Findata by submitting a data permit application. Description of the register data used in the study (names of registers and attribute codes) can be obtained from the corresponding author.
